Navigation Links
Validated pre-procedure risk score reduces bleeding complications and can shorten stays
Date:3/10/2013

A clinical decision support tool helped physicians identify patients at high risk of bleeding complications prior to undergoing a coronary intervention procedure and helped guide the use of bleeding avoidance strategies, leading to less complications and a shorter hospital stay, according to a study being presented March 10 at the American College of Cardiology Scientific Sessions.

More than 1.3 million percutaneous coronary interventions (PCIs) are performed each year in the United States. Bleeding during and after these procedures is a common risk (3 6%).

"Bleeding complications after PCI can lead to worse outcomes for the patient, including death, as well as an increase in the length of stay in the hospital, which leads to an increase in hospital costs," says the study's lead author Craig E. Strauss, MD, MPH, a research cardiologist at the Minneapolis Heart Institute Foundation and physician at the Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis.

Therefore, the cardiologists across the Allina Health System used a validated pre-PCI bleeding risk score to accurately identify high-risk patients, allowing them to employ strategies to avoid bleeding and improve patient outcomes. Among those strategies, bivalirudin (Angiomax, The Medicines Company) is a direct thrombin inhibitor that has been shown to reduce bleeding complications in PCI.

"This risk-stratification tool can be used real-time in the cath lab to identify and mitigate a patient's risk for bleeding around the time of the procedure," says Strauss. "The cath lab team uses a web-based calculator, which takes less than 1-2 minutes, and determines the risk category of each patient." Due to the ease of use, the tool achieved a high adoption rate of 92 percent at three high-volume PCI centers in Minnesota.

Among the 2,608 PCI cases performed at the three PCI centers, 24.4 percent of the patients were identified as high risk for bleeding complications. The use of bivalirudin as a bleeding avoidance strategy in high-risk patients increased from 24.2 percent pre-implementation of the risk-stratification protocol to 60.3 percent after the implementation of the protocol.

Among high bleeding risk patients, the researchers reported significant reductions in overall complications (22.8% vs. 14.9%), bleeding events within 72 hours (7.7% vs. 2.1%), and median length of hospital stay (2.9 vs. 2.3 days) following protocol implementation. There also was a reduction in the use of blood transfusions and death. Finally, the total variable costs decreased from approximately $15,000 to $14,200.

"This clinical decision support tool helps cardiologists objectively validate which patients are at high risk for bleeding complications based on existing evidence," Strauss says. "Previously, we could attempt to identify which patients were at risk based on clinical intuition, but this tool gives a much more accurate assessment, as shown through the improved patient outcomes. Furthermore, this tool can help reduce the variability in practice patterns among physicians that can be costly to the healthcare system."


'/>"/>

Contact: Steve Goodyear
612-863-1658
Minneapolis Heart Institute Foundation
Source:Eurekalert

Related medicine news :

1. First validated method for analyzing flavanols and procyanidins in cocoa products could help scientists and the industry in standardized reporting
2. Teleconcussion validated in Mayo Clinic case study
3. Study shows link between pre-pregnancy obesity and lower test scores
4. Delaying ADHD Meds Could Hurt Kids Math Scores
5. Kids Born Even a Little Early Have Lower School Scores: Study
6. Fit Brains, online portfolio of cognitive games, reaches milestone of 75 million brain scores
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Smoking in pregnancy tied to lower reading scores
9. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
10. New Study Finds Eating More Produce Boosts Mental Health, Underscores Value of Health Enhancement Systems Approach
11. Score Points for Hosting a Healthy Super Bowl Party
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... CARMEL, IN (PRWEB) , ... August 18, 2017 , ... ... 36th annual list, the most prestigious ranking of the nation's fastest-growing private companies. This ... in the exclusive Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Beyond Our Imaginations: The ... “Beyond Our Imaginations: The Infinite God” is the creation of published author, Mark Lawrence, ... country. , Lawrence shares, “The problem with becoming a greater man of God is ...
(Date:8/18/2017)... ... ... the Snake”: an entertaining and moral-based short story about an unkind snake learning a ... Jr., a husband, father and grandfather who served as a U.S. Marine, U.S. Army ... for children and teens. My goal is to teach kids to use good judgement ...
(Date:8/17/2017)... Delaware (PRWEB) , ... August 17, 2017 , ... When ... well actually, stretcher side nurse, she took with her a dream to make nursing ... of healthcare. Specifically, ensuring communication skills were integrated into healthcare provider education. ...
(Date:8/17/2017)... ... August 17, 2017 , ... Brookfield, ... for healthcare, hospitality and education, is celebrating its 30th year in business this ... begun at manufacturing companies Square D, Allis Chalmers and Johnson Controls. Following his ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results ... and updated its financial outlook for fiscal 2017. ... third quarter, Hill-Rom reported earnings of $0.09 per diluted ... prior-year period. These results reflect after-tax special items, including ... to the non-cash write-down of assets associated with the ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
Breaking Medicine Technology: